Ronawk Offering Free Samples of T-Blocks to Slash Stem Cell Expansion Costs & Labor Hours

OLATHE, Kansas — Ronawk, innovators in stem cell expansion technologies, has launched a trial program to provide its patented tissue-blocks (T-Blocks) to commercial cell producers and regenerative medicine partners. Their T-Blocks are a 3D matrix consumable product that enable the stem cell industry by providing means to increase stem cell production by 3,600 times vs. traditional expansion methods.

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration. The pace never slows when your mission is to enable lifesaving science!

Fate Therapeutics Gets FDA Clearance of IND Application for World’s First iPSC-derived CAR T-Cell Therapy

SAN DIEGO, July 09, 2020 — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT819, an allogeneic iPSC-derived CAR T-cell therapy targeting CD19+ malignancies.

Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)

GOLDEN, CO  July 14, 2020 — Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. Following the treatment with AlloRx Stem Cells®, the patient experienced resolution of multiple organ failure, recovery from coma, and restoration of neurological, pulmonary, liver and renal function. 

FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy

Miami, FL (August 6, 2020) ­— Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19.

Stem Cell Treatment Now Available in the UK, as LifePlus Stem Cells Launches in London

July 21, 2020 — LifePlus Stem Cells is the first Stem Cell service in the UK to provide doctors and prescribers with quantifiable, quality assured autologous and allogeneic stem cells, with appropriate HTA and MHRA licenses. Patients in the UK can now benefit from Stem Cell treatments prescribed as a medicine, which can be used for a wide range of conditions. Stem cell has been used for over 40 years for haematological conditions, with patients travelling around the world to reap the benefits of this pioneering treatment.

Direct Biologics Receives FDA Approval to Initiate ‘EXIT COVID-19,’ a Phase II Investigational New Drug Trial with ExoFlo™

AUSTIN, Texas — Direct Biologics, LLC, is announcing that it has received approval from FDA that it may proceed with a Phase II trial under an Investigational New Drug (IND) application for the use of ExoFlo™, a bone marrow-derived extracellular vesicle and exosome product, in the treatment of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). The ExoFlo Infusion Treatment for COVID-19 (EXIT COVID-19) Associated ARDS trial will be a multi-center, double-blind, randomized, placebo-controlled clinical trial.

BioStem Life Sciences Signs Manufacturing Agreement for Amniotic Membrane Allograft Platform

Pompano Beach, FL – August 11th, 2020 — BioStem Technologies, Inc. (OTC PINK: BSEM) a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, announced that its subsidiary, Blue Tech Industries, Inc. (doing business as BioStem Life Sciences), has signed a Master Service Agreement with a new customer to manufacture the customer’s amniotic membrane platform for the next two years, in a deal estimated to be worth up to $2.4 million to BioStem. 

What is CAR-T Cell Therapy? A New Way to Treat Cancer.

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients across the globe. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

San Diego, July 28, 2020 — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program.

Vita Therapeutics Receives Orphan Drug Designation from FDA for Allogenic iPSC-based Therapy

BALTIMORE, July 23, 2020 — Vita Therapeutics, Inc. has received orphan drug designation (ODD) from the U.S. FDA for VTA-110, a novel regenerative therapy for the treatment of Duchenne’s Muscular Dystrophy. VTA-110, is a first-in-class allogenic iPSC-based therapy that has shown the ability to repair and regenerate healthy muscle in preclinical studies and has the potential to benefit patients with DMD. The company plans to continue to progress this treatment towards clinical trials and plans to bring it forward for other congenital muscular dystrophy diseases.

Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chairman

LOUISVILLE, Colo., July 28, 2020  — Roy J. Bostock, former Chairman of Yahoo!, Vice Chairman of Delta Airlines and a director of Morgan Stanley, has joined the cellular medicine startup GID BIO that has a potentially break-through treatment for osteoarthritis in late-stage regulatory review. Bostock was elected chairman of the board to succeed J. William Futrell, M.D., co-founder and chairman since 2011 who will continue as a board director.

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update

MELBOURNE, Australia, May 08, 2020 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated guidance on its wider clinical development pipeline.

Global Cord Blood Banking Industry Report 2020 (Recently Released)

Published August 2020, this comprehensive report is designed to serve the needs of cord blood industry investors, executives, and strategic partners. It presents the number of units stored in inventory by the largest cord blood banks worldwide, the number of cord blood units (CBUs) released for HSC transplantation on an annual basis, utilization of cord blood and cord tissue in clinical trials, the economic models of public and private banks, critical analysis of emerging technologies, the future scope for companion products, and so much more. Using 15 years of historical data, it presents a detailed market size determination with segmentation by geography, indication, and type of bank (public vs. private), including projections through 2027.

*Would you like to advertise in this newsletter? If so, contact Info@BioInformant.com.